Scholarlink

<p>Isolated rapid eye movement sleep behavior disorder (iRBD) is recognized as a prodromal stage of alpha-synucleinopathies. While glymphatic dysfunction has been investigated in Parkinson’s disease, its role in iRBD remains incompletely understood. This study evaluated the association between glymphatic function and the speed-modulating effect to alpha-synucleionpathy conversion. Fifty-six patients (67.2 ± 7.1 [mean age ± SD]) with an iRBD and 48 control subjects (61.5 ± 10.0) underwent brain magnetic resonance imaging. Glymphatic function was evaluated using the diffusion tensor imaging along the perivascular space (DTI-ALPS) method with manual acquisition of the ALPS-index. The mean time from symptom onset to MRI acquisition (T<sub>1</sub>) was 7.05 ± 5.08 years, while among converters the mean time from symptom onset to phenoconversion (T<sub>2</sub>) was 11.07 ± 5.68 years. Higher ALPS-index was positively correlated with longer iRBD symptom duration (rho = 0.409, <i>p</i> = 0.002). Although the ALPS-index did not predict phenoconversion in the entire cohort, post-hoc analysis of converters revealed that patients with higher ALPS-index exhibited more than nine years longer time to conversion than patients with lower ALPS-index (χ² = 13.075, <i>p</i> &lt; 0.001). These findings suggest that preserved glymphatic function may be associated with prolonged prodromal stability in iRBD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Higher glymphatic system activity is linked to longer prodromal stage in isolated REM sleep behavior disorder: a possible protective factor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Veronika Rottova,
  • Stanislav Marecek,
  • Tomas Krajca,
  • Jiri Keller,
  • Karel Sonka,
  • Petr Dusek,
  • Jiri Nepozitek

摘要

Isolated rapid eye movement sleep behavior disorder (iRBD) is recognized as a prodromal stage of alpha-synucleinopathies. While glymphatic dysfunction has been investigated in Parkinson’s disease, its role in iRBD remains incompletely understood. This study evaluated the association between glymphatic function and the speed-modulating effect to alpha-synucleionpathy conversion. Fifty-six patients (67.2 ± 7.1 [mean age ± SD]) with an iRBD and 48 control subjects (61.5 ± 10.0) underwent brain magnetic resonance imaging. Glymphatic function was evaluated using the diffusion tensor imaging along the perivascular space (DTI-ALPS) method with manual acquisition of the ALPS-index. The mean time from symptom onset to MRI acquisition (T1) was 7.05 ± 5.08 years, while among converters the mean time from symptom onset to phenoconversion (T2) was 11.07 ± 5.68 years. Higher ALPS-index was positively correlated with longer iRBD symptom duration (rho = 0.409, p = 0.002). Although the ALPS-index did not predict phenoconversion in the entire cohort, post-hoc analysis of converters revealed that patients with higher ALPS-index exhibited more than nine years longer time to conversion than patients with lower ALPS-index (χ² = 13.075, p < 0.001). These findings suggest that preserved glymphatic function may be associated with prolonged prodromal stability in iRBD.